FDA approves Mounjaro to cut cardiovascular risk in type 2 diabetes
The tirzepatide label now covers cardiovascular risk reduction in adults with type 2 diabetes, extending it beyond glycemic control.
DO
By Daniel Okafor · Regulatory Correspondent
Aug 28 03:00 ETSource: Yahoo Finance
The wire
- 01Eli Lilly said the FDA approved Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes.
- 02A cardiovascular indication strengthens the case for coverage and prescribing in diabetes patients with existing heart risk, alongside semaglutide's similar labeling.
- 03Trial details, the specific endpoint and the population studied were not spelled out in the announcement; prescribers should check the updated label.
From the source
Read at finance.yahoo.comFDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
